Lonza, a global partner to the pharmaceutical, biotech, and nutraceutical markets, added clinical bottling and labeling capabilities at its Small Molecules site in Bend, OR. Building upon the recent investment in the early-phase clinical manufacturing facility, the offering now includes new bottling equipment for filling tablets and powder-filled capsules. The additional equipment aims to further support customers in the early stages of development.
FDA Issues Form 483 to Lonza Group
Wolfgang Wienand has joined Lonza Group as its new Chief Executive Officer (CEO), succeeding Albert M. Baehny, who took on the role of CEO ad interim in October 2023 and was Chairman of the Board of Directors of Lonza from 2018 to May 2024.
Lonza to Enhance Governance with Updates to its Board Committee Structure
Annexon`s neurological disease drug succeeds in late-stage study
Basel, Switzerland, 14 May 2024 – In its quarterly qualitative update, Lonza reported a softer Q1, with performance across H1 expected to align with the Full-Year 2024 trajectory.
Basel, Switzerland, 8 May 2024 – Today, Lonza Group Ltd held its Annual General Meeting (AGM), led by the outgoing Chairman of the Board of Directors, Albert M. Baehny. 40.28% of the share capital was represented at the AGM, with attending and represented shareholders collectively holding a total of 29,994,055 shares.
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets, today announced the launch of its AI-enabled Route Scouting Service offering. The offering aims to streamline synthetic route identification for novel APIs by combining Lonza’s global chemical supply chain intelligence and in-house expertise with AI technology from Elsevier (Reaxys).
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon